Flotations fail to bounce back
2022 saw just 19 initial public offerings of drug developers, the lowest total since 2012.
Ash 2022 preview – waiting for Editas
Data on the group’s sickle cell project do not feature in the regular abstracts, while Bluebird walks away from its short hairpin contender.
Foghorn sounds another warning about the class of ‘20
In 2020 76 biotech floats raised a combined $12.7bn. Foghorn is not the first to show that much of the faith was misplaced.
The year of the small buyout
Biopharma takeouts in the $1-5bn range jumped in 2021, as rising valuations made their mark.
